NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 4, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=110309&from=4 C ...

诉讼背景 - 针对Elanco Animal Health Incorporated及其高管提起的联邦证券法诉讼 [1] - 诉讼涉及《1934年证券交易法》第10(b)和20(a)条款 [2] - 诉讼案件名为Barpar v Elanco Animal Health Incorporated et al 案件编号24-cv-02912 在马里兰州美国地方法院审理 [2] 诉讼内容 - 诉讼涉及Elanco公司开发的治疗动物疾病的产品 [3] - 公司两款重要产品Zenrelia和Credelio Quattro正在接受FDA审查 [3] - Zenrelia用于治疗犬类皮炎 Credelio Quattro是广谱口服驱虫药 [3] - 公司曾表示FDA拥有完成审查所需的所有数据 预计在2024年6月底前获得批准 [4] - 2024年6月27日公司宣布FDA不会在6月批准这两款药物 Zenrelia将附带安全警告 [4] 市场影响 - 消息公布后Elanco股价下跌超过21% 从2024年6月26日的17.97美元跌至6月27日的14.27美元 [5] 法律行动 - 投资者可在2024年12月6日前申请成为案件首席原告 [2] - Bleichmar Fonti & Auld LLP律所正在调查Elanco及其高管是否就FDA批准事宜向投资者作出重大虚假或误导性陈述 [5]

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- A federal lawsuit has been filed in the U.S. District Court of Maryland against Elanco Animal Health Inc. and specific executives, accusing them of making false and misleading statements between November 7, 2023, and June 26, 2024. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbss ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=110017&fro ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-h ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=109662 ...

文章核心观点 - 领先的证券法律事务所Bleichmar Fonti & Auld LLP宣布已对Elanco Animal Health Incorporated(纽交所代码:ELAN)及其高管提起诉讼,指控其可能违反联邦证券法 [1][2] - Elanco公司开发用于治疗动物疾病的产品,其两款重要的研发管线产品正在等待美国FDA审批,但公司此前表示FDA已有所有数据完成审查,预计2024年6月前获批,但后来公司宣布FDA将不会在6月批准这两款药品,其中一款还将带有安全警示 [3][4] - 由于这一消息,Elanco股价在2024年6月27日下跌超过21% [5] 公司概况 - Elanco Animal Health Incorporated是一家专注于动物健康的公司,主要开发用于治疗动物疾病的产品 [3] - 公司两款重要的研发管线产品分别是Zenrelia(治疗犬类皮肤炎)和Credelio Quattro(广谱口服驱虫药,可预防跳蚤、蜱和内寄生虫) [3] 监管审批情况 - 公司此前表示FDA已有所有数据完成审查,预计2024年6月前获批 [4] - 但后来公司宣布FDA将不会在2024年6月批准这两款药品,其中一款Zenrelia还将带有安全警示 [4] 股价影响 - 由于Elanco公司发布的上述消息,其股价在2024年6月27日下跌超过21%,从前一交易日的17.97美元下跌至14.27美元 [5]